Exact Sciences Future Growth
Future criteria checks 4/6
Exact Sciences is forecast to grow earnings and revenue by 61.9% and 11.1% per annum respectively. EPS is expected to grow by 62.4% per annum. Return on equity is forecast to be 6.5% in 3 years.
Key information
61.9%
Earnings growth rate
62.4%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 11.1% |
Future return on equity | 6.5% |
Analyst coverage | Good |
Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,642 | 164 | 533 | 685 | 12 |
12/31/2025 | 3,225 | 6 | 332 | 467 | 21 |
12/31/2024 | 2,833 | -161 | 144 | 285 | 22 |
12/31/2023 | 2,500 | -204 | 32 | 156 | N/A |
9/30/2023 | 2,406 | -282 | -24 | 139 | N/A |
6/30/2023 | 2,301 | -432 | -108 | 73 | N/A |
3/31/2023 | 2,200 | -517 | -298 | -88 | N/A |
12/31/2022 | 2,084 | -624 | -438 | -224 | N/A |
9/30/2022 | 2,005 | -716 | -443 | -300 | N/A |
6/30/2022 | 1,938 | -735 | -437 | -300 | N/A |
3/31/2022 | 1,852 | -745 | -330 | -199 | N/A |
12/31/2021 | 1,767 | -596 | -238 | -102 | N/A |
9/30/2021 | 1,760 | -793 | -117 | 34 | N/A |
6/30/2021 | 1,712 | -829 | 30 | 156 | N/A |
3/31/2021 | 1,546 | -720 | 19 | 109 | N/A |
12/31/2020 | 1,491 | -824 | 71 | 136 | N/A |
9/30/2020 | 1,321 | -327 | -89 | 0 | N/A |
6/30/2020 | 1,131 | -165 | -238 | -111 | N/A |
3/31/2020 | 1,062 | -136 | -262 | -87 | N/A |
12/31/2019 | 876 | -213 | -284 | -112 | N/A |
9/30/2019 | 724 | -216 | -271 | -88 | N/A |
6/30/2019 | 623 | -221 | -248 | -62 | N/A |
3/31/2019 | 526 | -219 | -250 | -105 | N/A |
12/31/2018 | 454 | -175 | -219 | -69 | N/A |
9/30/2018 | 399 | -143 | -203 | -69 | N/A |
6/30/2018 | 353 | -124 | -167 | -70 | N/A |
3/31/2018 | 308 | -119 | -158 | -77 | N/A |
12/31/2017 | 266 | -114 | -141 | -72 | N/A |
9/30/2017 | 214 | -130 | N/A | -98 | N/A |
6/30/2017 | 169 | -141 | N/A | -118 | N/A |
3/31/2017 | 133 | -155 | N/A | -121 | N/A |
12/31/2016 | 99 | -167 | N/A | -130 | N/A |
9/30/2016 | 79 | -170 | N/A | -133 | N/A |
6/30/2016 | 63 | -175 | N/A | -145 | N/A |
3/31/2016 | 50 | -169 | N/A | -141 | N/A |
12/31/2015 | 39 | -158 | N/A | -134 | N/A |
9/30/2015 | 27 | -150 | N/A | -135 | N/A |
6/30/2015 | 14 | -139 | N/A | -119 | N/A |
3/31/2015 | 6 | -120 | N/A | -104 | N/A |
12/31/2014 | 2 | -100 | N/A | -81 | N/A |
9/30/2014 | 1 | -80 | N/A | -60 | N/A |
6/30/2014 | 2 | -59 | N/A | -46 | N/A |
3/31/2014 | 3 | -52 | N/A | -40 | N/A |
12/31/2013 | 4 | -47 | N/A | -40 | N/A |
9/30/2013 | 4 | -48 | N/A | -40 | N/A |
6/30/2013 | 4 | -50 | N/A | -43 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: EXK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EXK is expected to become profitable in the next 3 years.
Revenue vs Market: EXK's revenue (11.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: EXK's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXK's Return on Equity is forecast to be low in 3 years time (6.5%).